STOCKHOLM, Dec. 11, 2020 /PRNewswire/ -- OncoZenge AB
(publ) ("OncoZenge"), Moberg Pharma AB (publ)'s subsidiary, has
today resolved on a directed share issue in accordance with the
press release from November
16th, 2020 (the "Directed Issue"). The Directed
Issue of MSEK 10 is the first step of the secured financing in
OncoZenge of MSEK 70 in total. The share issue is carried out to
secure OncoZenge's initial working capital requirements ahead of
the listing on Nasdaq First North Growth Market, which is planned
to take place during the first quarter of 2021.
On November 16th, 2020,
it was announced that OncoZenge, through binding commitments, has
secured financing in a total amount of approximately MSEK 70 ahead
of its spin-off and separate listing, of which MSEK 10 through the
Directed Issue and the remaining approximately MSEK 60 through a
rights issue in connection with the contemplated separate listing
of OncoZenge.
The Board of Directors of OncoZenge has today, based on the
authorization from an extraordinary general meeting on November 16th, 2020, resolved to carry
out the Directed Issue. In total, OncoZenge will issue no more than
100,000 shares at a subscription price of SEK 100 per share, which means that OncoZenge
will receive issue proceeds in an amount of no more than MSEK 10.
The largest investors in the Directed Issue are John Fällström,
Linc AB and Östersjöstiftelsen. Based on the subscription price in
the Directed Issue, the value of OncoZenge before the Directed
Issue amounts to approximately MSEK 50. Subscription and payment of
the new shares will take place in December
2020.
Following the Directed Issue, the total number of shares and
votes in OncoZenge will amount to 600,000 shares and votes. The
dilution effect for the current shareholders in OncoZenge will be
approximately 16.7 percent. The reason for the deviation from the
shareholders' preferential rights is to raise adequate working
capital in a time and cost-efficient manner, to broaden OncoZenge's
shareholder base and to secure investment commitments for the
remaining MSEK 60 ahead of the listing.
For the financing of an upcoming clinical phase 3 study and
other activities, OncoZenge also intends to carry out a fully
guaranteed rights issue, which is expected to raise approximately
MSEK 60 to the Company before costs. The valuation in the rights
issue will be approximately MSEK 60, i.e. the same valuation
as in the Directed Issue, adjusted for the issue proceeds of MSEK
10. The subscription period for the rights issue is expected to
commence directly after the first day of trading in OncoZenge's
shares. Further details on the terms and the timetable is intended
to be announced in January 2021.
For additional information, please contact:
Anna Ljung, CEO Moberg Pharma, telephone: +46 707 66 60 30,
e-mail: anna.ljung@mobergpharma.se
Pirkko Tamsen, CEO OncoZenge,
telephone: +46 760 09 84 99,
e-mail: pirkko.tamsen@oncozenge.se
About this information
The information was submitted for publication, through the agency
of the contact persons set out above, at 8.00 a.m. CET on December
11th, 2020.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/moberg-pharma/r/oncozenge-raises-msek-10-ahead-of-spin-off-and-separate-listing,c3252554
The following files are available for download:
https://mb.cision.com/Main/1662/3252554/1346838.pdf
|
OncoZenge raises MSEK
10 ahead of spin-off and separate listing
|
View original
content:http://www.prnewswire.com/news-releases/oncozenge-raises-msek-10-ahead-of-spin-off-and-separate-listing-301191019.html
SOURCE Moberg Pharma